h5n1 whole virus influenza vaccine adjuvanted

An **inactivated, adjuvanted whole virus vaccine** developed for prevention of influenza A (H5N1), commonly known as avian influenza or "bird flu." This vaccine comprises the entire H5N1 influenza virus rendered inactive, combined with an adjuvant (such as AS03 or MF59), designed to elicit a robust immune response with a lower antigen dose. The mechanism of action involves induction of neutralizing anti-hemagglutinin antibodies and priming of cellular immunity. The adjuvants (emulsion-based, e.g., AS03 or MF59) enhance both humoral and cellular immune responses, enabling dose-sparing benefits crucial for pandemic preparedness. This vaccine is primarily targeted at adults at increased risk of H5N1 exposure, with specific stockpiling for pandemic scenarios. Its manufacturing follows similar processes to established inactivated influenza vaccines using egg or cell culture-based platforms, with the adjuvant supplied in a separate vial for combination before administration. Safety and immunogenicity data suggest robust antibody induction and tolerable side effect profiles[1][5].

Other names

h5n1 whole virion inactivated influenza vaccine adjuvantedh-5n1 whole virion inactivated influenza vaccine adjuvantedh 5n1 whole virion inactivated influenza vaccine adjuvantedwhole inactivated h5n1 influenza vaccine adjuvanted